A 56-week randomized, double-blind, placebo-controlled trial of liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
A first-in-human phase I trial of the NPY2 receptor agonist BI 1820237, alone or with low-dose liraglutide, in 95 men with overweight or obesity, reporting safety, tolerability, and additive effects on gastric emptying. PICO summary and expert commentary.
A small randomized trial finds baseline IL-1β in mononuclear cells predicts the degree of MASLD improvement after weight loss in obesity with prediabetes or early type 2 diabetes. PICO summary and expert commentary.
A Sanofi-sponsored post hoc analysis of the LixiLan-L-CN trial reports that iGlarLixi lowered residual hyperglycaemia more than insulin glargine alone in Chinese adults with type 2 diabetes. PICO summary and expert commentary.
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide’s effect in high-risk type 2 diabetes. PICO summary and expert commentary.
A Phase 2 randomised trial in 145 adults found once-weekly ecnoglutide lowered HbA1c by up to 2.39% versus 0.55% with placebo over 20 weeks. PICO summary and expert commentary.
A SURMOUNT-2 subpopulation analysis of 41 Japanese adults with type 2 diabetes and obesity, in which once-weekly tirzepatide produced significant 72-week weight loss versus placebo, tempered by a very small sample. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China asked whether baseline traits modify the glycaemic effect of once-weekly semaglutide versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
A small double-blind RCT in 38 patients with type 2 diabetes and coronary disease found pre-operative liraglutide gave better intra-operative glucose control and described regional epicardial fat microRNA patterns. PICO summary and expert commentary.